AMR Sept Banner v2

ASM Attends UN General Assembly

ASM President, Susan Sharp, Ph.D., joined global leaders at the United Nations General Assembly in New York today in a historical meeting to focus on the commitment to fight AMR.
Read

UN General Assembly Focuses on AMR

Leaders at the UN General Assembly draft a plan for coordinated, cross-cutting efforts to improve the current state of AMR.
Read

Superbugs are a 'Fundamental Threat'

If antibiotics were telephones, we would still be calling each other using clunky rotary dials and copper lines," Stefano Bertuzzi, CEO of ASM, told NBC News.
Read
Become a member today!
JOIN ASM
Submit Abstracts for Biothreats 2017
SUBMIT
Antibacterial Development Conference
REGISTER

 

campadelli-fiume gabriellaDr. Campadelli Fiume's research focuses on the molecular basis of herpes simplex virus (HSV) entry into susceptible cells, and on engineering of candidate oncolytic HSVs retargeted to tumor-specific receptors. HSV entry is a multistep process. First, gD binds to one of its receptors and triggers virion-cell fusion. Fusion is executed by the conserved glycoproteins gH/gL and gB. Major accomplishments by the labs were the discovery of nectin as HSV receptor, and the triggering activity of receptor-bound gD, including the identification of gD profusion domain. Current aims include identification of the role of gH/gL in fusion. Starting from this background we have modified gD and re-addressed this molecule to the tumor-specific receptor HER-2. She has provided the first proof of principle evidence that retargeted HSVs exert antitumor activity in vivo.

TPL_asm2013_SEARCH

91007